Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecularly Tailored Therapy vs Standard of Care for Metastatic Pancreatic Cancer
NCT02967770Phase 2Withdrawn
- Sponsor
- Georgetown University
- Start
- Nov 2016
- Primary completion
- Aug 2018
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Georgetown University. Primary endpoint: 4 month progression free survival rate. Planned start Nov 2016; status: withdrawn.
02
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02967770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02967770.